These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33260301)

  • 1. The Release of a Soluble Glycosylated Protein from Glycogen by Recombinant Lysosomal α-Glucosidase (rhGAA) In Vitro and Its Presence in Serum In Vivo.
    Murray AK
    Biomolecules; 2020 Nov; 10(12):. PubMed ID: 33260301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.
    Yi H; Sun T; Armstrong D; Borneman S; Yang C; Austin S; Kishnani PS; Sun B
    J Mol Med (Berl); 2017 May; 95(5):513-521. PubMed ID: 28154884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacological chaperone AT2220 increases recombinant human acid α-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease.
    Khanna R; Flanagan JJ; Feng J; Soska R; Frascella M; Pellegrino LJ; Lun Y; Guillen D; Lockhart DJ; Valenzano KJ
    PLoS One; 2012; 7(7):e40776. PubMed ID: 22815812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease.
    McVie-Wylie AJ; Lee KL; Qiu H; Jin X; Do H; Gotschall R; Thurberg BL; Rogers C; Raben N; O'Callaghan M; Canfield W; Andrews L; McPherson JM; Mattaliano RJ
    Mol Genet Metab; 2008 Aug; 94(4):448-455. PubMed ID: 18538603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice.
    Zhu Y; Li X; McVie-Wylie A; Jiang C; Thurberg BL; Raben N; Mattaliano RJ; Cheng SH
    Biochem J; 2005 Aug; 389(Pt 3):619-28. PubMed ID: 15839836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conjugation of mannose 6-phosphate-containing oligosaccharides to acid alpha-glucosidase improves the clearance of glycogen in pompe mice.
    Zhu Y; Li X; Kyazike J; Zhou Q; Thurberg BL; Raben N; Mattaliano RJ; Cheng SH
    J Biol Chem; 2004 Nov; 279(48):50336-41. PubMed ID: 15383547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endolysosomal N-glycan processing is critical to attain the most active form of the enzyme acid alpha-glucosidase.
    Selvan N; Mehta N; Venkateswaran S; Brignol N; Graziano M; Sheikh MO; McAnany Y; Hung F; Madrid M; Krampetz R; Siano N; Mehta A; Brudvig J; Gotschall R; Weimer JM; Do HV
    J Biol Chem; 2021; 296():100769. PubMed ID: 33971197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reveglucosidase alfa (BMN 701), an IGF2-Tagged rhAcid α-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease.
    Peng J; Dalton J; Butt M; Tracy K; Kennedy D; Haroldsen P; Cahayag R; Zoog S; O'Neill CA; Tsuruda LS
    J Pharmacol Exp Ther; 2017 Feb; 360(2):313-323. PubMed ID: 27856936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient therapy for refractory Pompe disease by mannose 6-phosphate analogue grafting on acid α-glucosidase.
    Basile I; Da Silva A; El Cheikh K; Godefroy A; Daurat M; Harmois A; Perez M; Caillaud C; Charbonné HV; Pau B; Gary-Bobo M; Morère A; Garcia M; Maynadier M
    J Control Release; 2018 Jan; 269():15-23. PubMed ID: 29108866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
    Raben N; Fukuda T; Gilbert AL; de Jong D; Thurberg BL; Mattaliano RJ; Meikle P; Hopwood JJ; Nagashima K; Nagaraju K; Plotz PH
    Mol Ther; 2005 Jan; 11(1):48-56. PubMed ID: 15585405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycosylation-independent lysosomal targeting of acid α-glucosidase enhances muscle glycogen clearance in pompe mice.
    Maga JA; Zhou J; Kambampati R; Peng S; Wang X; Bohnsack RN; Thomm A; Golata S; Tom P; Dahms NM; Byrne BJ; LeBowitz JH
    J Biol Chem; 2013 Jan; 288(3):1428-38. PubMed ID: 23188827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1,6-
    Kok K; Kuo CL; Katzy RE; Lelieveld LT; Wu L; Roig-Zamboni V; van der Marel GA; Codée JDC; Sulzenbacher G; Davies GJ; Overkleeft HS; Aerts JMFG; Artola M
    J Am Chem Soc; 2022 Aug; 144(32):14819-14827. PubMed ID: 35917590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production of recombinant human acid α-glucosidase with high-mannose glycans in gnt1 rice for the treatment of Pompe disease.
    Jung JW; Huy NX; Kim HB; Kim NS; Van Giap D; Yang MS
    J Biotechnol; 2017 May; 249():42-50. PubMed ID: 28363873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-dimensional tissue-engineered human skeletal muscle model of Pompe disease.
    Wang J; Zhou CJ; Khodabukus A; Tran S; Han SO; Carlson AL; Madden L; Kishnani PS; Koeberl DD; Bursac N
    Commun Biol; 2021 May; 4(1):524. PubMed ID: 33953320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysregulation of multiple facets of glycogen metabolism in a murine model of Pompe disease.
    Taylor KM; Meyers E; Phipps M; Kishnani PS; Cheng SH; Scheule RK; Moreland RJ
    PLoS One; 2013; 8(2):e56181. PubMed ID: 23457523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease.
    De Groot AS; Desai AK; Lelias S; Miah SMS; Terry FE; Khan S; Li C; Yi JS; Ardito M; Martin WD; Kishnani PS
    Front Immunol; 2021; 12():636731. PubMed ID: 34220802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved efficacy of a next-generation ERT in murine Pompe disease.
    Xu S; Lun Y; Frascella M; Garcia A; Soska R; Nair A; Ponery AS; Schilling A; Feng J; Tuske S; Valle MCD; Martina JA; Ralston E; Gotschall R; Valenzano KJ; Puertollano R; Do HV; Raben N; Khanna R
    JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30843882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjunctive β2-agonist treatment reduces glycogen independently of receptor-mediated acid α-glucosidase uptake in the limb muscles of mice with Pompe disease.
    Farah BL; Madden L; Li S; Nance S; Bird A; Bursac N; Yen PM; Young SP; Koeberl DD
    FASEB J; 2014 May; 28(5):2272-80. PubMed ID: 24448824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy.
    Prater SN; Patel TT; Buckley AF; Mandel H; Vlodavski E; Banugaria SG; Feeney EJ; Raben N; Kishnani PS
    Orphanet J Rare Dis; 2013 Jun; 8():90. PubMed ID: 23787031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease.
    Wang Z; Okamoto P; Keutzer J
    Mol Genet Metab; 2014 Feb; 111(2):92-100. PubMed ID: 24044919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.